Treprostinil-13C2, d1

Treprostinil-13C2, d is the 13C- and deuterium labeled Treprostinil. Treprostinil (UT-15) is a potent DP1 and EP2 agonist with EC50 values of 0.6±0.1 and 6.2±1.2 nM, respectively.

UT-15-13C2, d1

12352005

Isotope-Labeled Compounds; Prostaglandin Receptor

Isotope-Labeled Compounds

GPCR/G Protein; Others

Metabolism-protein/nucleotide metabolism

Inflammation/Immunology; Endocrinology

10 mM in DMSO

O=[13C](O)[13CH2]OC1=CC=CC2=C1C[C@]3([H])[C@]([C@@H](CC[C@@H](O)CCCCC)[C@]([2H])(O)C3)([H])C2

C21 13C2H33DO5

393.50

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-223.|[2]Ferrantino M, et al. Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother. 2011 Nov;12 (16) :2583-93.|[3]Ghonem N, et al. Treprostinil, a prostacyclin analog, ameliorates ischemia-reperfusion injury in rat orthotopic liver transplantation. Am J Transplant. 2011 Nov;11 (11) :2508-16.|[4]Kazemi Z, et al. Repurposing Treprostinil for Enhancing Hematopoietic Progenitor Cell Transplantation. Mol Pharmacol. 2016 Jun;89 (6) :630-44.|[5]Nikam VS, et al. Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension. Eur Respir J. 2010 Dec;36 (6) :1302-14.|[6]Smadja DM, et al. Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells. Thromb Haemost. 2015 Oct;114 (4) :735-47.|[7]Whittle BJ, et al. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol. 2012 Jul 1;84 (1) :68-75.

Room temperature

Isotope-Labeled Compounds

No Development Reported